The factors that affect the results of the response to rituximab treatment in ITP patients

Beyler, O.; Güneş, Ahmet Kürşad; Akat, Gulten Korkmaz; Ceran, Funda; Dağdaş, Simten; Özet, Gülsüm

doi:10.1016/j.htct.2020.09.047

Hematology, Transfusion and Cell Therapy

2020

DOI: 10.1016/j.htct.2020.09.047

|View full text |Cite

The factors that affect the results of the response to rituximab treatment in ITP patients

O. Beyler

Ahmet Kürşad Güneş

Gulten Korkmaz Akat

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Clinical efficacy of two different doses of rituximab as a treatment option in adult patients with chronic immune thrombocytopenia

El-Saied,

Dwidar,

Abdelaty

2024

Egypt J Intern Med

View full text Add to dashboard Cite

Background Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with a high incidence of chronicity among adults. Rituximab is recommended as a treatment option for chronic ITP with the best long-term effect compared with other therapies. However, the optimal dose of rituximab remains unclear. We retrospectively compared the response rate, incidence of relapse, and other clinical outcomes in 34 chronic ITP patients who received rituximab in different doses. Patients were divided into two groups according to rituximab dose (the low-dose group, 100 mg/week for 4 weeks, and the standard-dose group, 375 mg/m2 weekly for 4 weeks). Results Females represented 72.2% and 56.3% of patients in the low dose and the standard dose groups, respectively. The overall response in all patients was 88.2%. By the end of the second month of treatment, 77.8% achieved partial remission and 11.1% achieved complete remission in the low-dose group versus 68.8% and 18.8% in the standard-dose group. Similar incidence of sustained complete response after 6 months of treatment, 83.3% after low dose rituximab and 81.2% after the standard dose (p = 1.000). The incidence of relapse was similar between both groups. Conclusion Our findings demonstrate that both regimens had no statistically significant differences in overall response, relapse rate, and time to reach response. The low dose of rituximab is comparable to the standard high dose in efficacy and safety for the treatment of chronic ITP patients and can be a good option in centers with limited resources.

show abstract

Clinical efficacy of two different doses of rituximab as a treatment option in adult patients with chronic immune thrombocytopenia

El-Saied,

Dwidar,

Abdelaty

2024

Egypt J Intern Med

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The factors that affect the results of the response to rituximab treatment in ITP patients

Cited by 1 publication

References 0 publications

Clinical efficacy of two different doses of rituximab as a treatment option in adult patients with chronic immune thrombocytopenia

Clinical efficacy of two different doses of rituximab as a treatment option in adult patients with chronic immune thrombocytopenia

Contact Info

Product

Resources

About